Andrew Wallace

Andrew Wallace has extensive work experience in the field of scientific research and development. Andrew is currently working as a Principal Scientist at Taysha Gene Therapies, where they serve as the Technical Lead for method development and optimization of cell-based potency assays. Andrew collaborates with various teams within the company to support process development, CMC analytical development, QC, and CMC regulatory activities. Andrew also prepares reports in accordance with regulatory guidance regarding potency method development and validation.

Prior to their current role, Andrew worked at Catalent Pharma Solutions for several years. As a Principal Scientist, they held the position of Project Director and Technical Lead, overseeing method transfer, development, optimization, validation, and sample testing under non-GMP and GMP/GLP conditions. In addition, they supervised a team of analysts and played a crucial role in supporting business development through customer interactions and quote development. Andrew has received several honors and awards for their work at Catalent, including the Savvy Street Smarts Award, Team of the Year Award, and Bunsen Burner Award.

Before joining Catalent, Andrew served as a Senior Scientist and Lead Scientist at the same company. In these roles, they were responsible for various aspects of method transfer, development, optimization, validation, and sample testing. Andrew also contributed to the writing of protocols, methods, and reports, as well as maintained communication with customers. Furthermore, Andrew played a part in business development efforts through customer interactions and quote development.

Prior to their industry experience, Andrew worked as an Assistant Professor of Environmental and Molecular Toxicology at North Carolina State University. In this role, they managed a research laboratory focused on investigating the toxicity of chemotherapeutic drugs, pesticides, and plastics. Andrew conducted experiments to characterize receptor/transcription factor function and developed biochemical and immunological methods. Additionally, Andrew supervised phase I human metabolism and metabolic interaction studies using advanced analytical techniques.

Early in their career, Andrew worked as a Postdoctoral Fellow at the National Institute of Environmental Health Sciences. Their research during this time focused on the glucocorticoid receptor (GR) and the mechanisms behind hormone-dependent down-regulation of GR protein. Andrew investigated the degradation of GR by the proteasome complex and identified key protein motifs recognized by the proteasome-ubiquitination pathway leading to GR ligand-dependent protein degradation.

Overall, Andrew Wallace has a diverse work experience that spans both academia and industry. Andrew has demonstrated expertise in method development, optimization, and validation, as well as experience in managing research projects and supervising teams.

Andrew Wallace completed their Bachelor of Science in Biology from Indiana University Bloomington from 1987 to 1991. Andrew then pursued a Ph.D. in Toxicology from the University of Rochester School of Medicine and Dentistry, which they completed from 1991 to 1998.